达格列净在2型糖尿病合并高血压患者中的临床应用

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (44 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical application of Dapagliflozin in patients with type 2 diabetes mellitus and hypertension.Methods A total of 285 patients with type 2 diabetes mellitus and hypertension were enrolled as the research objects from January 2018 to December 2019 in the Department of Endocrinology,Beijing Jiangong Hospital and were divided into the Dapagliflozin group(142 cases)and Sitagliptin group(143 cases)according to the random number table method.Patients in the Dapagliflozin group were treated with Metformin Hydrochloride Tablets+Dapagliflozin,and patients in the Sitagliptin group were treated with Metformin Hydrochloride Tablets+Sitagliptin.After 24 weeks of treatment,changes of glycosylated hemoglobin(HbA1c),fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PG),systolic blood pressure(SBP),diastolic blood pressure(DBP)and body mass index(BMI)of patients between the two groups were compared.The occurrence of hypoglycemia,hypotension and urinary tract infection was compared between the two groups.Results Finally,133 cases were included in the Dapagliflozin group and 133 cases in the Sitagliptin group.After treatment,the HbA1c and 2 h PG of patients in the Dapagliflozin group were higher than those in the Sitagliptin group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in FBG between the two groups after treatment(P>0.05).The HbA1c,FBG,and 2 h PG of the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).The SBP and DBP of patients in the Dapagliflozin group after treatment were lower than those in the Sitagliptin group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in BMI between the two groups after treatment(P>0.05).The SBP and DBP of the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).The BMI in the Dapagliflozin group after treatment was lower than that before treatment in this group,and the difference was statistically significant(P<0.05).After treatment,the incidence of urinary tract infection in the Dapagliflozin group was higher than that in the Sitagliptin group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of hypoglycemia between the two groups after treatment(P>0.05).There was no hypotension in the two groups.Conclusion When Dapagliflozin is used in patients with type 2 diabetes and hypertension,it is easy to cause urinary tract infections.But its hypoglycemic effect is definite,especially its hypotensive and weight reduction effect is obvious and there are fewer hypoglycemia and hypotension events.As a whole,it is clinically relatively safe.

Key words： Dapagliflozin Diabetes mellitus Hypertension Clinical application

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAO Yan-hong
	WU Qing
	LI Yun
	WANG Ying-li
	ZHANG Ying
	LUO Ya-hui
	LIU Yan-dong
	LI Yin

Cite this article:

HAO Yan-hong,WU Qing,LI Yun, et al. Clinical application of Dapagliflozin in patients with type 2 diabetes mellitus and hypertension[J]. 中国当代医药, 2021, 28(18): 12-16.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I18/12

[14]	张俭，陈静，刘洁英.西格列汀联合二甲双胍对2型糖尿病患者FPG、2hPG、HbA1c 的影响[J].现代医学与健康研究（电子版），2020，4（7）：55-56.
[15]	王汝龙，母义明，胡欣.2型糖尿病治疗的新选择-DPP-4抑制剂[J].中国药学杂志，2014，49（8）：702-704.
[16]	郝兆虎，邵海琳，黄霄，等.达格列净与西格列汀对胰岛素控制不佳的超重及肥胖2型糖尿病患者的疗效观察[J].中华糖尿病杂志，2019，11（9）：592-596.
[17]	李金超.达格列净联合二甲双胍治疗对2型糖尿病患者代谢指标的影响[J].医药论坛杂志，2019，40（7）：146-148.
[1]	江丽姣，于倩倩，尹文强，等.我国居民慢性病变化趋势分析——基于国家五次卫生服务调查报告[J].中国卫生事业管理，2018，35（11）：874-876，880.
[2]	赵艳芳，王卓群，杨静，等.中国2013年18～49 岁育龄妇女2型糖尿病患病率、知晓率、治疗率和控制率状况分析[J].中华流行病学杂志，2018，39（2）：213-217.
[3]	王淳秀，吴晓光，刘宏军，等.北京市2013-2014年15 岁及以上居民高血压患病率、知晓率、治疗率和控制率调查[J].中华流行病学杂志，2018，39（2）：179-183.
[4]	张洁，何青芳，王立新，等.浙江省成人高血压合并糖尿病患病率及心血管病风险分析[J].预防医学，2018，30（2）：109-112.
[5]	Wiviott SD，Raz I，Bonaca MP，et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med，2019，380（4）：347-357.
[6]	Wiviott SD，Raz I，Bonaca MP，et al.The design and rationale for the Dapagliflozin Effect on Cardiovascular Events（DECLARE）TIMI 58 Trial[J].Am Heart J，2018，200：83-89.
[7]	Wilding JPH，Rigney U，Blak BT，et al.Glycaemic，weight，and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract，2019，155：107 791.
[8]	罗海荣，顾荣领，谭超容，等.达格列净的合成[J].精细石油化工，2019，36（4）：53-57.
[9]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[10]	中国高血压防治指南修订委员会，高血压联盟，中华医学会心血管病学分会中国医师协会高血压专业委员会，等.中国高血压防治指南（2018年修订版）[J].中国心血管杂志，2019，24（1）：24-56.
[11]	蓝裕平，张燕.人口增长、城市化进程与中国经济发展[J].国际融资，2020，（4）：31-37.
[12]	杨慧霞，王俊平.1982-2012年中国居民膳食摄入变化[J].食品工业，2020，41（6）：244-248.
[13]	张瑾，黄志龙.我国人口发展趋势及对策研究[J].宏观经济管理，2014，（1）：59-61.
[18]	邓宁，胡庆芬，梁彩虹，等.达格列净片联合盐酸二甲双胍对2型糖尿病患者的临床研究[J].中国临床药理学杂志，2019，35（18）：2016-2018.
[19]	范晓霞，姚勇利，胡耀嘉，等.超重和肥胖2型糖尿病伴微量白蛋白尿患者使用达格列净或沙格列汀控制血糖疗效和安全性的观察[J].中国糖尿病杂志，2020，28（2）：85-88.
[20]	孔文强，文露，张春燕，等.卡格列净、恩格列净、达格列净治疗T2DM 患者安全性的网状Meta 分析[J].第三军医大学学报，2018，40（19）：1792-1804.
[21]	张爱玲，李朵璐，周玉冰，等.达格列净与2型糖尿病患者泌尿生殖系统感染相关性的Meta 分析[J].医药导报，2019，38（5）：650-655.
[22]	杨洋，魏鹏翔，张村，等.达格列净联合常规降糖药治疗糖尿病有效性和安全性的Meta 分析[J].中国循证医学杂志，2019，19（12）：1436-1445.